Bal Pharma Limited
National Stock Exchange of IndiaTotal Valuation
Bal Pharma Limited carries a market capitalization of 1.22B, placing it among publicly traded companies globally. Its enterprise value stands at 2.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.22B |
| Enterprise Value | 2.44B |
Share Statistics
Bal Pharma Limited currently has 15.92M shares outstanding.
| Shares Outstanding | 15.92M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Bal Pharma Limited trades at a trailing price-to-earnings ratio of 15.14. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 5.98.
| PE Ratio | 15.14 |
| PS Ratio | 0.31 |
| PB Ratio | 5.98 |
| P/TBV Ratio | 1.46 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Bal Pharma Limited trades at an EV/EBITDA multiple of 11.71 and an EV/FCF ratio of 13.61. The EV/Sales ratio of 0.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.71 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.78 |
| EV / EBITDA | 11.71 |
| EV / EBIT | 11.71 |
| EV / FCF | 13.61 |
Financial Position
Bal Pharma Limited maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 193.94, indicating elevated leverage, while an interest coverage ratio of 1.24 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.05 |
| Quick Ratio | 0.04 |
| Debt / Equity | 193.94 |
| Debt / EBITDA | 7.66 |
| Interest Coverage | 1.24 |
Financial Efficiency
| Return on Equity (ROE) | 21.25 |
| Return on Assets (ROA) | 1.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 2.26 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | -3.86M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Bal Pharma Limited's stock has declined approximately -24.05376% over the past 52 weeks. The 50-day moving average sits at 83.26, while the 200-day moving average is 77.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | -24.05376% |
| 50-Day Moving Average | 83.26 |
| 200-Day Moving Average | 77.07 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Bal Pharma Limited generated 3.12B in revenue and converted that into 62.84M in net income, yielding earnings per share of 4.01. EBITDA reached 208.24M, while operating income came in at 208.24M.
| Revenue | 3.12B |
| Gross Profit | 1.54B |
| Operating Income | 208.24M |
| Pretax Income | 59.34M |
| Net Income | 62.84M |
| EBITDA | 208.24M |
| EBIT | 208.24M |
| Earnings Per Share (EPS) | 4.01 |
Balance Sheet
Bal Pharma Limited holds 109.32M in cash and equivalents against 1.60B in total debt, resulting in a net debt position of 1.57B. Total book value stands at 159.21M, with working capital of 130.06M providing operational flexibility.
| Cash & Cash Equivalents | 109.32M |
| Total Debt | 1.60B |
| Net Debt | 1.57B |
| Equity (Book Value) | 159.21M |
| Book Value Per Share | 10.11 |
| Working Capital | 130.06M |
Margins
Bal Pharma Limited operates with a gross margin of 49.32, reflecting its pricing power and cost economics. The operating margin of 6.68 and net profit margin of 2.02 provide insight into operational efficiency.
| Gross Margin | 49.32 |
| Operating Margin | 6.68 |
| Pretax Margin | 1.90 |
| Profit Margin | 2.02 |
| EBITDA Margin | 6.68 |
Scores
Bal Pharma Limited posts an Altman Z-Score of 1.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.30 |